Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The blood-brain barrier (BBB) is suggested to be compromised in Alzheimer's disease (AD). The concomitant presence of vascular amyloid beta (Aβ) pathology, so called cerebral amyloid angiopathy (CAA), also predisposes impairment of vessel integrity. Additionally, immunotherapy against Aβ may lead to further damage of the BBB. To what extent this affects the BBB passage of molecules is debated. The current study aimed to investigate BBB integrity to large molecules in transgenic mice displaying abundant Aβ pathology and age matched wild type animals, with or without acute anti-Aβ antibody treatment. Animals were administered a single i.v. injection of PBS or 3D6 (10 mg/kg), i.e. the murine version of the clinically investigated Aβ antibody bapineuzumab, supplemented with [125I]3D6. Three days post injections, a 4 kDa FITC and a 150 kDa Antonia Red dextran were administered i.v. to all animals. After termination, fluorescent detection in brain and serum was used for the calculation of dextran brain-to-blood concentration ratios. Further characterization of antibody fate and the presence of CAA were investigated using radioactivity measurements and Congo red staining. BBB passage of large molecules was equally low in wild type and transgenic mice, suggesting an intact BBB despite Aβ pathology. Neither was the BBB integrity affected by acute 3D6 treatment. However, CAA was confirmed in the transgenes and local antibody accumulations were observed in the brain, indicating CAA-antibody interactions. The current study shows that independently of Aβ pathology or acute 3D6 treatment, the BBB is intact, without extensive permeability to large molecules, including the 3D6 antibody.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 3×
“The antibody binds the N-terminal neoepitope of amyloid-β (Aβ), resulting from βsecretase cleavage of the Aβ protein precursor, and targets both fibrillar and soluble Aβ, which are known hallmarks of AD neuropathology (Bard et al., 2000).”
BackgroundInfluentialTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 3×
“While also showing potential beneficial effects in phase II clinical trials, bapineuzumab later failed in phase III due to nonsignificant changes on primary outcomes and incidence of unfavorable side effects (18-20).”
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“Animals Heterozygous female and male transgenic mice, expressing the human Aβ protein precursor with the Arctic (E693G) and Swedish (KM670/671NL) mutations (tg-ArcSwe) (25-27), were used at an age of 18-19 months together with their WT littermates.”
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 1×
“Heterozygous female and male transgenic mice, expressing the human Aβ protein precursor with the Arctic (E693G) and Swedish (KM670/671NL) mutations (tg-ArcSwe) (Lord et al., 2006; Mullan et al., 1992; Nilsberth et al., 2001), were used at an age of 18–19 months together with their WT littermates.”
MethodA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · cited 3×
“While also showing potential beneficial effects in phase II clinical trials, bapineuzumab later failed in phase III due to nonsignificant changes on primary outcomes and incidence of unfavorable side effects (18-20).”
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 1×
“The BBB and the functioning of the NVU are proposed to be disrupted in AD, with for instance tight junction loss and dysregulated transport across the barrier (Montagne et al., 2017; Nelson et al., 2016).”
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622 · cited 1×
“Bispecific antibodies engineered for enhanced delivery s across the BBB are being developed mainly to increase antibody brain concentrations and thus therapeutic effect (35, 52).”
Cited by
Yue, Q., Leng, X., Xie, N., Zhang, Z., Yang, D., & Hoi, M. P. M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70079 · Cited by 48
Elbaz, M., Ad-El, N., Chulanova, Y., Brier, D., Goldsmith, M., Bismuth, M., Brosque, A., Sher, D., Gutkin, A., Bar-On, D., et al. (2025) · doi:10.1101/2025.01.23.634427 · Cited by 43
Xiong, M., Roshanbin, S., Rokka, J., Schlein, E., Ingelsson, M., Sehlin, D., Eriksson, J., & Syvänen, S. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118302 · Cited by 24
Self-citation
Metadata
- Authors
- Gustafsson, S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund-Udenaes, M., Sehlin, D., & Syvänen, S.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 143
- Pages
- 1-9
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2890201119
- Cited by
- 44
- References
- 25
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy. https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.09.001
- The paper
- Gustafsson, S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund-Udenaes, M., Sehlin, D., & Syvänen, S. (2018). Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.09.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.